Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1003)	7/14/1998 9:12:00 PM
From: cm	Respond to of 1491

That IS The Point, Now Isn't It...? As always the discussion is here is more than worth the price of admission. And it's a boon to have Ariella and Neuroinv and Yosi and others to keep us all apprised from a variety of angles and perspectives. I added to my position today. And will buy even more on weakness. This stock is in a hole... a media hole... unnoticed... and misunderstood, to boot. But, I would not mistake its media hole for a hole in either its science or reasonable prospects. It is frustrating, of course, as the stock languishes. But, I am as convinced as ever that this is an unrecognized winner in the making. Best Regards, PARSians c m

To: NeuroInvestment who wrote (1003)	7/14/1998 10:37:00 PM
From: Don Walster	Read Replies (1) \| Respond to of 1491

Thank you, Neuroinvestment, for your answer which my question prompted. I think it is important to clear the air in this area which you have helped to do. I assume that from what you have said, the fact that it is 3 or 4 years out is of little consequence in so far as the value of the stock is concerned. Kindest regards, Don Walster

To: NeuroInvestment who wrote (1003)	7/15/1998 3:17:00 AM
From: Merav	Read Replies (1) \| Respond to of 1491

Agree with Neuroinvestment (1003). What counts is the behavior of humans when Dexanabinol is tested on them; the FDA will behave according to those results, as will strategic partners and investors.